

**Louisiana Medicaid**  
**Pain Management – Cytokine and CAM Antagonists**

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request clinical authorization for cytokine or CAM antagonists.

Additional Point-of-Sale edits may apply.

*These agents may have **Black Box Warnings** and/or may be subject to **Risk Evaluation and Mitigation Strategy (REMS)** under FDA safety Regulations. Please refer to individual prescribing information for details.*

---

*When currently posted criteria are not met, a clinical reviewer will consider the most current FDA-approved prescribing information for the requested agent when evaluating the request.*

**General approval criteria for both preferred and non-preferred cytokine and CAM antagonists (ALL criteria must be met):**

- An appropriate diagnosis is required, and the agent must be prescribed according to U.S. Food and Drug Administration approved indications, dosing, safety and monitoring regulations; **AND**
- By submitting the authorization request, the prescriber attests to the following:
  - The recipient will not receive the requested medication in combination with any other cytokine or CAM antagonist; **AND**
  - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
  - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
  - The recipient has no concomitant drug therapies or disease states that limit the use of the requested medication and will not receive the requested medication in combination with any other medication that is contraindicated or not recommended per FDA labeling; **AND**
- For those agents identified as non-preferred on the PDL, the following conditions apply:
  - There is no preferred alternative that is exactly the same chemical entity, formulation, strength, etc.; **AND**
  - **ONE** of the following is true and is **stated on the request**
    - The recipient had documented *intolerable side effects* or a documented *treatment failure* with an adequate trial (6-12 weeks) of **TWO** preferred agents, if the preferred agents are indicated for the specified diagnosis; **OR**
    - The recipient has a *contraindication* to the preferred agents indicated for the specified diagnosis.

## Approval criteria for specific diagnoses:

### Acute Graft versus Host Disease, Prophylaxis (Orencia®)

- The recipient is 2 years of age or older; **AND**
- The recipient is undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor; **AND**
- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a hematologist or oncologist; **AND**
- The prescriber **states on the request** that Orencia® will be used in combination with a calcineurin inhibitor (e.g., tacrolimus) and methotrexate.

### Alopecia Areata (Olumiant®)

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The recipient has at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than 6 months; **AND**
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or dermatologist; **AND**
  - The agent is not being given in combination with other JAK inhibitors (e.g., tofacitinib), biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine; **AND**
  - The recipient has an ANC  $\geq 1000/\text{mm}^3$ , an ALC  $\geq 500/\text{mm}^3$ , and hemoglobin  $\geq 8$  g/dL.

### Ankylosing Spondylitis [for Cimzia®, Cosentyx®, **Rinvoq®**, and Taltz®, this includes Non-Radiographic Axial Spondyloarthritis] (Avsola®, Cimzia®, Cosentyx®, Enbrel®, Humira®, Inflectra®, Remicade®, Renflexis®, **Rinvoq®**, Simponi®, Simponi Aria®, Taltz®, Xeljanz® tablet and Xeljanz® XR)

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
  - The recipient had documented intolerable side effects or a documented treatment failure with a non-steroidal anti-inflammatory agent (NSAID) during a single 3-month period; **OR**
  - The recipient has a contraindication to NSAIDs; **AND**
  - For Enbrel®, the quantity does not exceed 4 syringes every 28 days; **OR**
  - For Humira®, the quantity does not exceed 2 syringes every 28 days; **OR**
  - For Xeljanz® and Xeljanz® XR:
    - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
    - The recipient has an absolute lymphocyte count (ALC)  $\geq 500$  cells/ $\text{mm}^3$ , an ANC  $\geq 1,000$  cells/ $\text{mm}^3$ , and hemoglobin level  $\geq 9$  g/dL; **AND**
    - The recipient has had an inadequate response or intolerance to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab); **OR**
  - For Rinvoq®:

- The agent is not being given in combination with JAK inhibitors, biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
- The recipient has an ALC  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 8$  g/dL; **AND**
- The recipient has had an inadequate response or intolerance to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab).

#### **Atopic Dermatitis (Cibinqo™, Rinvoq®)**

- The recipient is 12 years of age or older on the date of the request; **AND**
- The following is true and is **stated on the request**:
  - The disease is refractory and moderate to severe; **AND**
  - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of **ONE** conventional systemic treatment, including biologics; **AND**
  - There has been a treatment failure or intolerable side effect with or contraindication to a preferred topical corticosteroid agent (see Dermatology – Steroids, Topical – Low, Medium, High and Very High Potency); **AND**
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a dermatologist, immunologist or allergist; **AND**
  - The agent is not being given in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants; **AND**
  - For Cibinqo™:
    - The dose does not exceed 200mg per day; **AND**
    - The recipient has a platelet count  $\geq 150,000$ /mm<sup>3</sup>, an ALC  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 8$  g/dL; **OR**
  - For Rinvoq®:
    - The dose does not exceed 30mg per day; **AND**
 The recipient has an ALC  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 8$  g/dL.

#### **Coronavirus Disease 2019 (COVID-19)**

- Olumiant® is indicated for the treatment of coronavirus disease 2019 (COVID-19) in **hospitalized adults** requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant® is not indicated and will not be approved for outpatient treatment of COVID-19.

#### **Crohn's Disease (Avsola®, Cimzia®, Entyvio®, Humira®, Inflectra®, Renflexis®, Remicade®, Skyrizi®, Stelara®)**

- For Avsola®, Humira®, Inflectra®, Renflexis® or Remicade®, the recipient is 6 years of age or older; **OR**
- For Cimzia®, Entyvio®, Skyrizi®, or Stelara®, the recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:

- The disease is moderate to severe (indicated by recent hospitalization, anemia requiring blood transfusion, significant weight loss, fever or malnutrition); **AND**
- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a gastroenterologist; **AND**
- The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of **ONE** conventional systemic treatment for Crohn's disease which includes but is not limited to corticosteroids, 5-aminosalicylates, 6-mercaptopurine, azathioprine, or methotrexate; **AND**
- For Humira®, the quantity does not exceed 3 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **OR**
- For Entyvio®, the recipient:
  - Had an inadequate response with, lost response to, or was intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; **OR**
  - Had an inadequate response with, was intolerant to, or demonstrated dependence on corticosteroids; **OR**
- For Skyrizi®, the following doses are not exceeded:
  - Induction dose of 600mg IV at Week 0, Week 4, and Week 8; **AND**
  - Maintenance dose of 360mg subcutaneous at Week 12, and every 8 weeks thereafter; **OR**
- For Stelara®, the recipient:
  - Failed or was intolerant to treatment with immunomodulators or corticosteroids, but never failed a TNF blocker; **OR**
  - Failed or was intolerant to treatment with one or more TNF blockers.

#### **Cytokine release syndrome (CRS), severe or life-threatening (Actemra®)**

- The recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The recipient has severe or life-threatening chimeric antigen receptor (CAR) T cell-induced CRS; **AND**
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or an oncologist or specialist in the area of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome; **AND**
  - Prior to the initiation of treatment with Actemra®, lab testing was performed consisting of an absolute neutrophil count (ANC), platelet count, and liver function tests (ALT/AST); **AND**
  - Adult recipients have an  $ANC \geq 2,000/mm^3$ , a platelet count  $\geq 100,000/mm^3$ , and the ALT/AST levels do not exceed 1.5 times the upper limit of normal (ULN); **AND**
  - Actemra® is prescribed according to U.S. Food and Drug Administration labeled dosing for CRS:
    - 12mg/kg for recipients weighing < 30kg
    - 8mg/kg for recipients weighing  $\geq 30kg$ ;
    - Up to a maximum of 800mg per infusion and a maximum of 4 doses up to at least 8 hours apart.

### **Deficiency of Interleukin-1 Receptor Antagonist (DIRA) (Arcalyst®, Kineret®)**

- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a specialist in the treatment of DIRA; **AND**
- For Arcalyst®:
  - The recipient weighs at least 10kg (current weight is stated on the request); **AND**
  - The maximum weekly dose does not exceed 320mg; **AND**
- For Kineret®, the maximum daily dose does not exceed 8mg/kg.

### **Enthesitis-Related Arthritis (Cosentyx®)**

- The recipient is 4 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
  - The recipient has a contraindication to or documented intolerance or failure with an adequate trial (6-12 weeks) of **AT LEAST ONE** disease modifying antirheumatic drug (DMARD) (such as methotrexate, corticosteroids, or azathioprine).

### **Giant cell arteritis (Actemra®)**

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
  - Prior to the initiation of treatment with Actemra®, lab testing was performed consisting of an ANC, platelet count, and liver function tests (ALT/AST); **AND**
  - The recipient has an ANC  $\geq 2,000/\text{mm}^3$ , a platelet count  $\geq 100,000/\text{mm}^3$ , and the ALT/AST levels do not exceed 1.5 times the upper limit of normal (ULN); **AND**
  - The recipient had an inadequate response to systemic corticosteroids (e.g., prednisone).

### **Hidradenitis Suppurativa (Humira®)**

- The recipient is 12 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The recipient has a diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage II or III); **AND**
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a dermatologist; **AND**
  - The quantity does not exceed 4 syringes every 28 days; **AND**
  - For Hurley stage II disease, the recipient had an inadequate response to conventional treatment for Hidradenitis Suppurativa, which may include, but is not limited to, oral tetracyclines, oral retinoids, and hormonal therapy.

### **Neuromyelitis Optica Spectrum Disorder (NMOSD) (Enspryng®, Uplizna®)**

- The recipient is 18 years of age or older; **AND**
- The following is true and is stated on the request:
  - The recipient has a diagnosis of neuromyelitis optica spectrum disorder; **AND**

- The recipient is anti-aquaporin-4 (AQP4) antibody positive; **AND**
- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist.

#### **Oral Ulcers Associated with Behçet's Disease (Otezla®)**

- The recipient is 18 years of age or older; **AND**
- The recipient has a diagnosis of Behçet's Disease; **AND**
- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
- The request states that the recipient has active oral ulcers.

#### **Periodic Fever Syndromes:**

- **Cryopyrin-Associated Periodic Syndromes (CAPS) (Arcalyst®, Kineret®, and Ilaris®) - The following is true and is **stated on the request**:**
  - For Kineret®:
    - The medication is being prescribed for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID), which has been confirmed by one of the following:
      - NLRP-3 [nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation; **OR**
      - Evidence of active inflammation which includes both clinical symptoms (e.g., rash, fever, arthralgia) and elevated acute phase reactants (e.g., ESR, CRP); **AND**
    - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or a specialist in the treatment of NOMID; **OR**
  - For Arcalyst® and Ilaris®:
    - The medication is being prescribed for the treatment of either Familial Cold Autoinflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS); **AND**
    - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or a specialist in the treatment of FCAS and MWS; **AND**
  - For Arcalyst®:
    - The recipient is 12 years of age or older; **OR**
  - For Ilaris®:
    - The recipient is 4 years of age or older; **AND**
    - The maximum dose is 150mg every 8 weeks.
- **Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS); OR Hyperimmunoglobulin D Syndrome (HIDS); OR Mevalonate Kinase Deficiency (MKD); OR Familial Mediterranean Fever (FMF) (Ilaris®)**
  - The recipient is 2 years of age or older; **AND**

- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or a specialist in the treatment of TRAPS, HIDS, MKD and FMF; **AND**
- The maximum dose is 300mg every 4 weeks.

**Plaque Psoriasis (Avsola®, Cimzia®, Cosentyx®, Enbrel®, Humira®, Ilumya®, Inflectra®, Otezla®, Remicade®, Renflexis®, Siliq®, Skyrizi®, Stelara®, Taltz® and Tremfya®)**

- For Avsola®, Cimzia®, Humira®, Ilumya®, Inflectra®, Otezla®, Remicade®, Renflexis®, Siliq®, Skyrizi® or Tremfya®, the recipient is 18 years of age or older; **OR**
- For Cosentyx®, Stelara® or Taltz®, the recipient is 6 years of age or older; **OR**
- For Enbrel®, the recipient is 4 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or dermatologist; **AND**
  - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of **AT LEAST ONE** of the following therapies: phototherapy, methotrexate, and/or cyclosporine; **AND**
  - The recipient has Body Surface Area (BSA) involvement of at least 3% or involvement of the palms, soles, head and neck or genitalia, causing disruption in normal activities and/or employment; **AND**
  - For Skyrizi®, the dose does not exceed 150mg at Week 0, Week 4 and every 12 weeks thereafter; **OR**
  - For Enbrel®:
    - For pediatric patients (4 to < 18 years old) – the quantity does not exceed 4 syringes every 28 days; **OR**
    - For adult (≥ 18 years old) plaque psoriasis patients, starting dose – the quantity does not exceed 8 syringes every 28 days for 3 months; **AND**
    - For adult (≥ 18 years old) plaque psoriasis patients, maintenance dose – the quantity does not exceed 4 syringes every 28 days; **OR**
  - For Humira®, the quantity does not exceed 3 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **OR**
  - For Cimzia®, Cosentyx®, Enbrel®, Humira®, Siliq®, Stelara®, Taltz®, or Tremfya®, the disease is chronic moderate to severe plaque psoriasis; **OR**
  - For Ilumya® or Skyrizi®, the recipient has a diagnosis of moderate-to-severe plaque psoriasis; **OR**
  - For Avsola®, Inflectra®, Remicade® or Renflexis®, the disease is chronic severe plaque psoriasis; **OR**
  - For Siliq®, the following criteria must be met:
    - The recipient has tried at least one traditional systemic agent for psoriasis (e.g., methotrexate, cyclosporine, acitretin tablets, or psoralen plus ultraviolet A light) for at least 3 months, (unless intolerant); **OR**
    - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (3 months) of a non-biologic agent indicated for psoriasis; **AND**
    - By submitting the authorization request, the prescriber attests to the following:

- The recipient does not have Crohn's Disease; **AND**
- The recipient has signed the Siliq® recipient-prescriber agreement form; **AND**
- All approval criteria for the REMS (Risk Evaluation and Mitigation Strategy) program have been met.

**Polyarticular Juvenile Idiopathic Arthritis (Actemra®, Enbrel®, Humira®, Orencia®, Simponi Aria®, Xeljanz® tablet and Xeljanz® oral solution)**

- The recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
  - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of methotrexate or corticosteroids; **AND**
  - For Enbrel®, the quantity does not exceed 4 syringes every 28 days; **OR**
  - For Humira®, the quantity does not exceed 2 syringes every 28 days; **OR**
  - For Xeljanz® tablet and Xeljanz® oral solution:
    - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
    - The recipient has an absolute lymphocyte count (ALC)  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 9$  g/dL; **AND**
    - The recipient has had an inadequate response or intolerance to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab).

**Psoriatic Arthritis (Avsola®, Cimzia®, Cosentyx®, Enbrel®, Humira®, Inflectra®, Orencia®, Otezla®, Remicade®, Renflexis®, Rinvoq®, Simponi®, Simponi Aria®, Skyrizi®, Stelara®, Taltz®, Tremfya®, Xeljanz® tablet and Xeljanz® XR)**

- For Avsola®, Cimzia®, Enbrel®, Humira®, Inflectra®, Orencia®, Otezla®, Remicade®, Renflexis®, Rinvoq®, Simponi®, Skyrizi®, Taltz®, Tremfya®, Xeljanz® tablet and Xeljanz® XR, the recipient is 18 years of age or older; **OR**
- For Stelara®, the recipient is 6 years of age or older; **OR**
- For Simponi Aria® and Cosentyx®, the recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a dermatologist or rheumatologist; **AND**
  - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of at least one non-biologic DMARD (such as methotrexate or leflunomide); **AND**
  - For Enbrel®, the quantity does not exceed 4 syringes every 28 days; **OR**
  - For Humira®, the quantity does not exceed 2 syringes every 28 days; **OR**
  - For Rinvoq®:
    - The dose does not exceed 15mg per day; **AND**
    - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
    - The recipient has an ALC  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 8$  g/dL; **AND**



- The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of methotrexate; **AND**
- The recipient has had an inadequate response or intolerance to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab); **OR**
- For Skyrizi®, the dose does not exceed 150mg at Week 0, Week 4 and every 12 weeks thereafter; **OR**
- For Xeljanz® and Xeljanz® XR:
  - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
  - The recipient has an absolute lymphocyte count (ALC)  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 9$  g/dL; **AND**
  - The recipient has had an inadequate response or intolerance to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab).

#### **Recurrent Pericarditis (Arcalyst®)**

- The recipient is 12 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a cardiologist; **AND**
  - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial of at least one standard of care therapy (such as NSAIDs and colchicine).

#### **Rheumatoid Arthritis (Actemra®, Avsola®, Cimzia®, Enbrel®, Humira®, Inflectra®, Kevzara®, Kineret®, Olumiant®, Orencia®, Remicade®, Renflexis®, Rinvoq®, Simponi®, Simponi Aria®, Xeljanz® tablet and Xeljanz® XR)**

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
  - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of at least one non-biologic DMARD (such as methotrexate, leflunomide, or azathioprine); **AND**
  - The agent is being used to treat moderately to severely active rheumatoid arthritis; **AND**
  - For Enbrel®, the quantity does not exceed 4 syringes every 28 days; **OR**
  - For Humira®, the quantity does not exceed 4 syringes every 28 days; **OR**
  - For Actemra®, the dose does not exceed 800mg per infusion; **OR**
  - For Rinvoq®:
    - The dose does not exceed 15mg per day; **AND**
    - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
    - The recipient has an ALC  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 8$  g/dL; **AND**

- The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of methotrexate; **AND**
- The recipient has had an inadequate response or intolerance to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab); **OR**
- For Xeljanz® tablet and Xeljanz® XR:
  - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
  - The recipient has an ALC  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 9$  g/dL; **AND**
  - The recipient has had an inadequate response or intolerance to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab); **OR**
- For Avsola®, Inflectra®, Remicade®, Renflexis®, Simponi®, or Simponi® Aria, the medication is being used in combination with methotrexate; **OR**
- For Kevzara®, the recipient has an ANC  $\geq 2000$ /mm<sup>3</sup>, a platelet count  $\geq 150,000$ /mm<sup>3</sup> and liver transaminases do not exceed 1.5 times the upper limit of normal (ULN); **OR**
- For Olumiant®:
  - The recipient has had an inadequate response to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab); **AND**
  - The agent is not being given in combination with other JAK inhibitors (e.g., tofacitinib), biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine; **AND**
  - The recipient has an ANC  $\geq 1000$ /mm<sup>3</sup>, an ALC  $\geq 500$ /mm<sup>3</sup>, and hemoglobin  $\geq 8$  g/dL.

#### **Still's Disease (Ilaris®) [Including Adult-Onset Still's Disease]**

- The recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
  - The maximum dose is 300mg every 4 weeks administered subcutaneously; **AND**
  - The recipient has a contraindication to or documented intolerance or failure with an adequate trial (6-12 weeks) of **AT LEAST ONE** disease modifying antirheumatic drug (DMARD) (such as methotrexate, corticosteroids, or azathioprine).

#### **Systemic Juvenile Idiopathic Arthritis (Actemra®, Ilaris®)**

- The recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
  - For Ilaris®, the maximum dose is 300mg every 4 weeks administered subcutaneously; **AND**

- The recipient has a contraindication to or documented intolerance or failure with an adequate trial (6-12 weeks) of **AT LEAST ONE** disease modifying antirheumatic drug (DMARD) (such as methotrexate, corticosteroids, or azathioprine).

#### **Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) (Actemra®)**

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a pulmonologist; **AND**
  - The maximum dose is 162mg given subcutaneously once a week.

#### **Ulcerative Colitis (Avsola®, Entyvio®, Humira®, Inflectra®, Remicade®, Renflexis®, Rinvoq®, Simponi®, Stelara®, Xeljanz® tablet and Xeljanz® XR)**

- For Entyvio®, Rinvoq®, Simponi®, Stelara®, Xeljanz® tablet or Xeljanz® XR, the recipient is 18 years of age or older; **OR**
- For Avsola®, Inflectra®, Remicade® or Renflexis®, the recipient is 6 years of age or older; **OR**
- For Humira®, the recipient is 5 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The disease is moderate to severe (indicated by recent hospitalization, anemia requiring blood transfusion, significant weight loss, fever or malnutrition); **AND**
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a gastroenterologist; **AND**
  - The recipient has a contraindication to documented intolerance or treatment failure with an adequate trial (6-12 weeks) of **AT LEAST ONE** conventional treatment for ulcerative colitis which may include but is not limited to 6-mercaptopurine, corticosteroids (such as prednisone or methylprednisolone), or azathioprine; **AND**
  - For Entyvio®, the recipient had an inadequate response with, lost response to, or was intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, was intolerant to, or demonstrated dependence on corticosteroids; **OR**
  - For Humira®, the quantity does not exceed 4 syringes every 28 days; **OR**
  - For Rinvoq®:
    - The agent is not being given in combination with JAK inhibitors, biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
    - The recipient has an ALC  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 8$  g/dL; **AND**
    - The recipient has had an inadequate response or intolerance to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab); **OR**
  - For Xeljanz® tablet and Xeljanz® XR:
    - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
    - The recipient has an ALC  $\geq 500$  cells/mm<sup>3</sup>, an ANC  $\geq 1,000$  cells/mm<sup>3</sup>, and hemoglobin level  $\geq 9$  g/dL; **AND**

- The recipient has had an inadequate response or intolerance to one or more TNF antagonists (e.g., adalimumab, certolizumab pegol, etanercept, golimumab or infliximab).

#### **Uveitis (Humira®)**

- The recipient has a diagnosis of non-infectious intermediate, posterior, and panuveitis; **AND**
- The recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
  - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, an ophthalmologist or a rheumatologist; **AND**
  - The quantity does not exceed 3 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **AND**
  - The recipient had an inadequate response to conventional treatment for uveitis, which may include antibiotics, antiviral medications, or corticosteroids.

#### **Reauthorization criteria for both preferred and non-preferred cytokine or CAM antagonists (Except for Orencia® when used for prophylaxis of acute graft vs host disease):**

- Recipient continues to meet initial approval criteria (general and drug/diagnosis specific); **AND**
- The prescriber **states on the request** that there is evidence of a positive response to treatment as indicated by improvement in signs and symptoms compared to baseline, or by halting of disease progression (no progression of disease signs and symptoms as compared to baseline).

**Initial Approval: 6 months**

**Reauthorization Approval: 12 months**

**Orencia® for prophylaxis of acute graft vs host disease: 28 days**

#### **References**

Actemra (tocilizumab) [package insert]. South San Francisco, CA: Genentech, Inc; February 2022. [https://www.gene.com/download/pdf/actemra\\_prescribing.pdf](https://www.gene.com/download/pdf/actemra_prescribing.pdf)

Arcalyst (rilonacept) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; May 2021. [https://www.arcalyst.com/sites/arcalyst.com/files/2021-08/PI\\_IFU.pdf](https://www.arcalyst.com/sites/arcalyst.com/files/2021-08/PI_IFU.pdf)

Avsola (infliximab-axxq) [package insert]. Thousand Oaks, CA: Amgen Inc; September 2021. [https://www.pi.amgen.com/~media/amgen/repositorysites/pi-amgen-com/avsola/avsola\\_pi\\_english.ashx](https://www.pi.amgen.com/~media/amgen/repositorysites/pi-amgen-com/avsola/avsola_pi_english.ashx)

Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of Acute and Recurrent Pericarditis. J Am Coll Cardiol 2020;75:76-92.

<https://www.jacc.org/doi/abs/10.1016/j.jacc.2019.11.021>

Cibinqo (abrocitinib) [package insert]. New York, NY: Pfizer Inc; January 2022.

[https://cdn.pfizer.com/pfizercom/USPI\\_Med\\_Guide\\_CIBINQO\\_Abrocitinib\\_tablet.pdf](https://cdn.pfizer.com/pfizercom/USPI_Med_Guide_CIBINQO_Abrocitinib_tablet.pdf)

Cimzia (certolizumab pegol) [package insert]. Smyrna, GA: UCB, Inc; September 2019.

[https://www.cimzia.com/sites/default/files/docs/CIMZIA\\_full\\_prescribing\\_information\\_1.pdf](https://www.cimzia.com/sites/default/files/docs/CIMZIA_full_prescribing_information_1.pdf)

Cosentyx (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; December 2021. [www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf](http://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf)

Donahue, K, et al. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. AHRQ Publication No. 18-EHC015-EF. PCORI Publication No. 2018-SR-02. Rockville, MD: Agency for Healthcare Research and Quality; July 2018. <https://doi.org/10.23970/AHRQEPCCER211>

Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corporation; April 2021.

[https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/enbrel/enbrel\\_pi.pdf](https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/enbrel/enbrel_pi.pdf)

Enspryng (satralizumab-mwge) [package insert]. South San Francisco, CA: Genentech, Inc; May 2021.

[https://www.gene.com/download/pdf/enspryng\\_prescribing.pdf](https://www.gene.com/download/pdf/enspryng_prescribing.pdf)

Hahn YS. Enthesitis-related Arthritis. *J Rheum Dis* 2018;25:221-230.

<https://doi.org/10.4078/jrd.2018.25.4.221>

Entyvio (vedolizumab) [package insert]. Deerfield, IL: Takeda Pharmaceuticals; August 2021.

<https://general.takedapharm.com/ENTYVIOPI>

Gottlieb, A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. *J Am Acad Dermatol*. 2008 May;58(5):851-64.

<https://www.aad.org/practicecenter/quality/clinical-guidelines/psoriasis>

Humira (adalimumab) [package insert]. North Chicago, IL: AbbVie Inc; February 2021.

<https://www.rxabbvie.com/pdf/humira.pdf>

Ilaris (canakinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals;

September 2020. <https://www.novartis.us/sites/www.novartis.us/files/ilaris.pdf>

Ilumya (tildrakizumab-asmn) [package insert]. , Cranbury, NJ: Sun Pharmaceutical Industries; July 2020.

[https://www.ilumya.com/pdfs/Sun\\_Pharma\\_ILUMYA\\_US\\_Prescribing\\_Information.pdf](https://www.ilumya.com/pdfs/Sun_Pharma_ILUMYA_US_Prescribing_Information.pdf)

Inflectra (infliximab-dyyb) [package insert]. New York, NY: Pfizer Labs; March 2022.

<https://labeling.pfizer.com/ShowLabeling.aspx?id=9271>

Kevzara (sarilumab) [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; April 2018.

<http://products.sanofi.us/kevzara/kevzara.pdf>

Kineret (anakinra) [package insert]. Stockholm, Sweden: Swedish Orphan Biovitrum AB;

December 2020. <https://www.kineretrx.com/pdf/Full-Prescribing-Information-English.pdf>

Megna M, Napolitano M, Patruno C, et al. Systemic Treatment of Adult Atopic Dermatitis: A Review. *Dermatol Ther (Heidelb)*. 2017;7(1):1-23. doi:10.1007/s13555-016-0170-1

Olumiant (baricitinib) [package insert]. Indianapolis, IN: Lilly USA, LLC; June 2022.

<http://pi.lilly.com/us/olumiant-uspi.pdf>

Orencia (abatacept) [package insert]. Princeton, NJ: Bristol-Myers Squibb; December 2021.

[https://packageinserts.bms.com/pi/pi\\_orencia.pdf](https://packageinserts.bms.com/pi/pi_orencia.pdf)

Otezla (apremilast) [package insert]. Summit, NJ: Celgene Corporation; December 2021.

[https://www.pi.amgen.com/~media/amgen/repositorysites/pi-amgen-com/otezla/otezla\\_pi\\_english.ashx](https://www.pi.amgen.com/~media/amgen/repositorysites/pi-amgen-com/otezla/otezla_pi_english.ashx)

Remicade (infliximab) [package insert]. Horsham, PA: Janssen Biotech; October 2021.

<https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf>

Renflexis (infliximab-abda) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; January 2022. [https://www.organon.com/product/usa/pi\\_circulars/r/renflexis/renflexis-pi.pdf](https://www.organon.com/product/usa/pi_circulars/r/renflexis/renflexis-pi.pdf)

Rinvoq (upadacitinib) [package insert]. North Chicago, IL: AbbVie Inc; ~~October~~ April 2022.

[https://www.rxabbvie.com/pdf/rinvoq\\_pi.pdf](https://www.rxabbvie.com/pdf/rinvoq_pi.pdf)

Siliq (brodalumab) [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals; April 2020.

<https://www.bauschhealth.com/Portals/25/Pdf/PI/Siliq-pi.pdf>

Simponi (golimumab) [package insert]. Horsham, PA: Janssen Biotech; September 2019.

<http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI-pi.pdf>

Simponi Aria (golimumab) [package insert]. Horsham, PA: Janssen Biotech; February 2021.

<http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI+ARIA-pi.pdf>

Singh, J, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research 2016;68(1):1-25 DOI: 10.1002/acr.22783

Skyrizi (risankizumab-rzaa) [package insert]. North Chicago, IL: AbbVie Inc.; June 2022.

[https://www.rxabbvie.com/pdf/skyrizi\\_pi.pdf](https://www.rxabbvie.com/pdf/skyrizi_pi.pdf)

Stelara (ustekinumab) [package insert]. Horsham, PA: Janssen Biotech August 2022.

<http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf>

Taltz (ixekizumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; November 2021.

<http://uspl.lilly.com/taltz/taltz.html#pi>

Tremfya (guselkumab) [package insert]. Horsham, PA: Janssen Biotech; July 2020.

<http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf>

Uplizna (inebilizumab-cdon) [package insert]. Gaithersburg, MD: Viela Bio, Inc; July 2021.

<https://www.hzndocs.com/Uplizna-Prescribing-Information.pdf>

U.S. National Library of Medicine. Neonatal Onset Multisystem Inflammatory Disease.  
<https://ghr.nlm.nih.gov/condition/neonatal-onset-multisystem-inflammatory-disease#sourcesforpage>

Ward, M, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care and Research 2016;68(2): 151-166.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123844/pdf/nihms822816.pdf>

Wu, J. Contemporary Management of Moderate to Severe Plaque Psoriasis. American Journal of Managed Care 2017;23:S403-S416.  
<https://www.ajmc.com/journals/supplement/2017/contemporary-management-of-moderate-to-severe-plaque-psoriasis/contemporary-management-of-moderate-to-severe-plaque-psoriasis>

Xeljanz oral solution, Xeljanz tablet and Xeljanz XR (tofacitinib) [package insert]. New York, NY; Pfizer Labs; December 2021.  
<http://labeling.pfizer.com/ShowLabeling.aspx?id=959>

Zouboulis C, et al. European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa. Journal of European Academy of Dermatology and Venereology. 2015 Apr. 29 (4):619-44. <https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.12966>

<b>Revision / Date</b>	<b>Implementation Date</b>
Removed diagnosis requirement at POS, add non-radiographic axial spondyloarthritis for Cimzia®, add max dose for Actemra® for RA, add severity to RA criteria / May 2019	August 2019
Incorporated Otezla® new indication for oral ulcers associated with Behçet’s Disease, modify age for ulcerative colitis for Inflectra® and Renflexis® / August 2019	November 2019
Added Stelara® to ulcerative colitis (new indication) and Taltz® to Ankylosing Spondylitis (new indication), added specialists to giant cell arteritis, oral ulcers with Bechet’s disease and TRAPS, HIDS, MKD and FMF / January 2020	May 2020
Combined Skyrizi® criteria with Cytokine and CAM Antagonists criteria, formatting changes / July 2020	July 2020
Modified age for Taltz® for plaque psoriasis, added diagnosis of non-radiographic axial spondyloarthritis to Cosentyx® and Taltz®, added diagnosis of Still’s Disease for Ilaris®, clarified diagnosis for Actemra®, updated references, formatting changes / June 2020	October 2020
Modified age for Stelara® for plaque psoriasis, added indication of active psoriatic arthritis to Tremfya®; updated references; incorporated Skyrizi® into the document / September 2020	January 2021
Modified age to Simponi Aria® for active psoriatic arthritis, added indication of polyarticular juvenile idiopathic arthritis; updated reference / September 2020	April 2021

Incorporated new formulation of Xeljanz® oral solution, added indication of polyarticular juvenile idiopathic arthritis; modified age for Simponi Aria®; formatting changes, updated references / November 2020	April 2021
Added Deficiency of Interleukin-1 Receptor Antagonist (DIRA) to Kineret® and Arcalyst®, updated references / January 2021	July 2021
Added Avsola®, Enspryng® and Uplizna®; updated age for Humira®, updated references / February 2021	July 2021
Added Recurrent Pericarditis to Arcalyst®, updated references / March 2021	July 2021
Added Systemic Sclerosis-Associated Interstitial Lung Disease for Actemra®, updated reference / March 2021	July 2021
Updated Cosentyx® age for plaque psoriasis, updated references / June 2021	January 2022
Updated criteria for Rinvoq® and all Xeljanz® formulations to include treatment failure with one or more TNF antagonist, added Rinvoq® to psoriatic arthritis (new indication) and Xeljanz® to ankylosing spondylitis (new indication), updated references / December 2021	April 2022
Added indication of prophylaxis for acute graft vs host disease for Orencia®, updated references / December 2021	April 2022
Added indication of atopic dermatitis for Rinvoq®, modified wording for Otezla® to include all adults with plaque psoriasis, added indication of psoriatic arthritis for Skyrizi®, updated age indication of psoriatic arthritis for Cosentyx®, added indication of enthesitis-related arthritis for Cosentyx®, added quantity limits for Humira® and Enbrel®, added COVID-19 statement about Olumiant®, updated references/ February 2022	July 2022
Moved Olumiant COVID-19 statement to criteria, added indication of ulcerative colitis and ankylosing spondylitis for Rinvoq®, added indication of Crohn's disease for Skyrizi®, removed prescriber attestations regarding Hepatitis B and TB testing, updated references / April 2022	October 2022
Added indication of alopecia areata for Olumiant®, updated psoriatic arthritis age indication for Stelara®, combined Cibinqo™ criteria with Cytokine and CAM Antagonists criteria, updated references / November 2022	January 2023
<u>Added indication of Non-Radiographic Axial Spondyloarthritis for Rinvoq®, updated references / October 2022</u>	<u>April 2023</u>